VSX2: A Potential Drug Target and Biomarker for Diseases (G338917)
![Review Report on VSX2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on VSX2 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
VSX2: A Potential Drug Target and Biomarker for Diseases
VSX2 is a protein that is found in the ceh-10 homeo domain containing homolog gene. This gene is located on chromosome 16 and has been shown to play a role in the development and progression of various diseases, including cancer. VSX2 has also been identified as a potential drug target and a biomarker for several diseases.
The ceh-10 homeo domain containing homolog gene is a member of the Wnt signaling pathway, which is a critical pathway for the development and maintenance of tissues in the body. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development of many diseases, including cancer.
VSX2 and the ceh-10 homeo domain containing homolog gene
VSX2 is a 21-kDa protein that is found in the ceh-10 homeo domain containing homolog gene. This gene is located on chromosome 16 and has been shown to play a role in the development and progression of various diseases, including cancer. VSX2 has also been identified as a potential drug target and a biomarker for several diseases.
The ceh-10 homeo domain containing homolog gene is a member of the Wnt signaling pathway, which is a critical pathway for the development and maintenance of tissues in the body. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development of many diseases, including cancer.
VSX2 and cancer
VSX2 has been shown to be involved in the development and progression of cancer. Several studies have shown that VSX2 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases.
VSX2 and diabetes
VSX2 has also been shown to be involved in the development and progression of diabetes. Several studies have shown that VSX2 is overexpressed in individuals with type 2 diabetes and that this overexpression is associated with the development of complications such as cardiovascular disease and neuropathy.
VSX2 and neurodegenerative diseases
VSX2 has also been shown to be involved in the development and progression of neurodegenerative diseases. Several studies have shown that VSX2 is overexpressed in individuals with Alzheimer's disease and other forms of neurodegenerative disease. This overexpression is thought to contribute to the development and progression of these diseases.
VSX2 as a drug target
VSX2 has been identified as a potential drug target for the treatment of various diseases, including cancer, diabetes, and neurodegenerative diseases. Several studies have shown that VSX2 plays a role in the development and progression of these diseases and that this role can be targeted by drugs.
VSX2 as a biomarker
VSX2 has also been identified as a potential biomarker for the development and progression of various diseases, including cancer, diabetes, and neurodegenerative diseases. Several studies have shown that VSX2 is overexpressed in individuals with these diseases and that this overexpression is associated with the development of complications.
Conclusion
VSX2 is a protein that is found in the ceh-10 homeo domain containing homolog gene. This gene is located on chromosome 16 and has been shown to play a role in the development and progression of various diseases, including cancer. VSX2 has also been identified as a potential drug target and a biomarker for several diseases. Further research is needed to fully understand the role of VSX2 in the development and progression of these diseases.
Protein Name: Visual System Homeobox 2
Functions: Acts as a transcriptional regulator through binding to DNA at the consensus sequence 5'-[TC]TAATT[AG][AG]-3' upstream of gene promoters (PubMed:27301076). Plays a significant role in the specification and morphogenesis of the sensory retina (By similarity). May play a role in specification of V2a interneurons during spinal cord development (By similarity). Mediates differentiation of V2a interneurons by repression of motor neuron gene transcription, via competitively binding to response elements that are activated by the ISL1-LHX3 complex, such as VSX1 (PubMed:17919464, PubMed:27477290). Acts as a positive transcriptional regulator of NXNL1; regulation is significantly increased in synergy with VSX1 (By similarity). Acts as a negative transcriptional regulator of MITF (By similarity). Represses SAG transcription by competitive inhibition of ISL1-LHX3 response elements (PubMed:16236706, PubMed:27477290). Binds to the photoreceptor conserved element-1 (PCE-1) in the promoter of rod photoreceptor arrestin SAG and acts as a transcriptional repressor (By similarity). Plays a significant role in the specification and morphogenesis of the sensory retina (By similarity). Involved in the development of retinal ganglion cells (RGCs) which leads to release of SHH by RGCs, promoting Hedgehog signaling and subsequent proliferation of retinal progenitor cells (By similarity). Participates in the development of the cells of the inner nuclear layer, by promoting postnatal differentiation of bipolar cells with a comparable inhibition of rod cell differentiation (By similarity). May play a role in the maintenance of neural retina identity during development by regulation of canonical Wnt genes and CTNNB1 localization, suggesting a role in the regulation of canonical Wnt signaling (PubMed:27301076)
The "VSX2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSX2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
VTA1 | VTCN1 | VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47